Please login to the form below

Not currently logged in
Email:
Password:

immunotherapies

This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.

BMS to test Vedanta’s bacterial therapy with Opdivo

BMS to test Vedanta’s bacterial therapy with Opdivo

In animal studies presented at this year’s Society for Immunotherapy of Cancer (SITC) meeting, VE800 on its own and alongside PD-1 inhibitors showed anti-tumour effects, including cytotoxic T ... For BMS, the alliance is just one of many seeking to

Latest news

More from news
Approximately 66 fully matching, plus 347 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    This agreement, which is to combine SQZ’s expertise in cell therapy with Roche’s expertise in immunotherapy will develop cancer products based on the combined technologies, and is anticipated to

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma. ... Open-minded culture. Like the new HQ’s

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    AZ isn’t a frontrunner overall in lung cancer immunotherapy – MSD consolidated its global lead by gaining a groundbreaking approval of Keytruda in China in July – but AZ has an ace

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as

  • Industry appointments Industry appointments

    Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen will consolidate the biotech’s manufacturing strategy. Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • Christian Pangratz to head up Sterna Biologicals Christian Pangratz to head up Sterna Biologicals

    Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior

More from appointments
Approximately 2 fully matching, plus 42 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 11 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics